Kiniksa Pharmaceuticals International plc is a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa Pharmaceuticals International plc is based in LONDON.
| Revenue (Most Recent Fiscal Year) | $423.24M |
| Net Income (Most Recent Fiscal Year) | $-43.19M |
| PE Ratio (Current Year Earnings Estimate) | 32.72 |
| PE Ratio (Trailing 12 Months) | 842.50 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 4.72 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.05 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 2.69% |
| Net Margin (Trailing 12 Months) | 0.90% |
| Return on Equity (Trailing 12 Months) | 1.05% |
| Return on Assets (Trailing 12 Months) | 0.80% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.57 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.16 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 2.38 |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.68 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.23 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.60 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.04 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 74.11M |
| Free Float | 34.48M |
| Market Capitalization | $2.50B |
| Average Volume (Last 20 Days) | 0.57M |
| Beta (Past 60 Months) | 0.14 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 53.48% |
| Percentage Held By Institutions (Latest 13F Reports) | 53.95% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |